This aligns with the inflammatory perspective, prompting an investigation into whether LG2 could mitigate the onset of EMT/fibroblast myofibroblast transition (FMT), enhance ECM degradation, reduce ECM deposition, and ultimately alleviate PF by suppressing the expression of the TNF-α pathway. The gene discussed is TNF; the disease is pemphigus foliaceus.